Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421755 | 1.00 | HTR2C (0.47) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25421751 | 1.00 | HTR2C (0.47) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25421677 | 0.88 | MEN1 (0.49) | HTR2CPPARDPPARA | |
| SCHEMBL30488439 | 0.88 | MEN1 (0.49) | HTR2CPPARDPPARA | |
| SCHEMBL30488430 | 0.88 | MEN1 (0.49) | HTR2CPPARDPPARA | |
| SCHEMBL25421675 | 0.88 | MEN1 (0.49) | HTR2CPPARDPPARA | |
| SCHEMBL31494787 | 0.88 | MAOB (0.48) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25630191 | 0.88 | MAOB (0.48) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25420145 | 0.86 | HTR2C (0.66) | HTR2CHTR2APPARDPPARAMAOB | |
| SCHEMBL25420142 | 0.86 | HTR2C (0.66) | HTR2CHTR2APPARDPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023114238-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GRIN2C, GAP43 | HTR2C 79/4885HTR2A 74/4885PPARD 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.